TBXT and neoplasm: Oncolytic viruses have been genetically engineered to express cytokines, costimulatory molecules, immune checkpoint inhibitors, or bispecific T-cell engager (BiTE) molecules to boost anti-tumour immune response and suppress tumour tolerance.